BofA raises target for AbbVie stock to USD 289.00
Published on 10/05/2026 at 10:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie (ISIN US00287Y1091) was trading at EUR 233.95 at Lang & Schwarz on October 5, 2026 at 9:48 a.m. CEST, up 0.17 percent from the prior close of EUR 233.55. BofA analyst Tim Anderson raised the AbbVie price target from USD 282.00 to USD 289.00 on September 29, 2026, according to Markets Insider.
BofA sees a higher target
The revised target keeps BofA's Buy rating in place. Anderson pointed to AbbVie's loss-of-exclusivity profile, recent acquisitions and investment in immunology, antibody-drug conjugates and neuroscience as factors supporting the longer-term growth case, according to Markets Insider.
The target is above the Lang & Schwarz euro quote, but the currencies are different and the comparison is not a return calculation. For investors, the key question is whether newer medicines can offset pressure on older products.
Second-quarter revenue rose 10.20 percent
AbbVie reported USD 16.99 billion of revenue in the second quarter of 2026, up 10.20 percent from the same quarter a year earlier. Adjusted earnings per share came in at USD 3.65, ahead of the USD 3.61 consensus estimate, according to MarketBeat.
The same report said AbbVie set third-quarter 2026 adjusted earnings-per-share guidance at USD 3.84 to USD 3.88. That range gives the upcoming results a clear benchmark, particularly for the performance of Skyrizi and Rinvoq as the company manages the post-Humira transition.
Results date and valuation context
AbbVie is scheduled to report third-quarter 2026 results before the market opens on October 30, 2026, according to MarketBeat. The company also declared a quarterly dividend of USD 1.73 per share, with an October 15, 2026 ex-dividend date.
On the primary exchange, AbbVie trades on the NYSE in USD, as identified by Investing.com. The finance quote showed a USD 464.3 billion market capitalization and a USD 190.75 to USD 269.39 52-week range as of October 2, 2026.
Stock remains below its yearly high
AbbVie was trading at EUR 233.95 at Lang & Schwarz on October 5, 2026 at 9:48 a.m. CEST, versus the EUR 233.55 prior close at Lang & Schwarz on October 2, 2026. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.
AbbVie stock at a glance
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 5, 2026, 9:48 a.m. CEST): EUR 233.95
- Change versus prior close: plus 0.17 percent
- Prior close Lang & Schwarz (October 2, 2026): EUR 233.55
- Market capitalization: USD 464.3 billion (as of October 2, 2026)
- 52-week range: USD 190.75-269.39 (as of October 2, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
